Challenges in multiple sclerosis; How to define occurence of progression

Clinical Neurology and Neurosurgery

Volumn 115, Issue SUPPL.1, 2013, Pages

  Brinar, V V ^a,b   Barun, B ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b Association for MS Research Zagreb   (Croatia)

^c KBC Zagreb   (Croatia)

Author keywords

MRI in MS brain atrophy; Multiple sclerosis; Natural history studies; Pathology; Therapy of MS

Indexed keywords

IMMUNOMODULATING AGENT; MYELIN;

ARTICLE; BRAIN ATROPHY; BRAIN CORTEX LESION; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; WHITE MATTER LESION;

MRI IN MS BRAIN ATROPHY; MULTIPLE SCLEROSIS; NATURAL HISTORY STUDIES; PATHOLOGY; THERAPY OF MS;

ANIMALS; BRAIN; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 84890027447     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2013.09.017     Document Type: Article

References (85)

1. A. Compston, and A. Coles Multiple sclerosis Lancet 25 372 2008 1502 1517
2. H. Lassmann, and J. van Horssen The molecular basis of neurodegeneration in multiple sclerosis FEBS Lett 585 2011 3715 3723
3. B.G. Weinschenker, B. Bass, and G.P. Rice The natural history of multiple sclerosis: a geographically based study I. Clinical course and disability Brain 112 1989 133 146
4. B.G. Weinschenker, B. Bass, and G.P. Rice The natural history of multiple sclerosis: a geographically based study.2. Predictive value of the early clinical course Brain 112 1989 133 146
5. F.D. Lublin, M. Baier, and G. Cutter Effect of relapse on development of residual deficit in multiple sclerosis Neurology 61 2003 1528 1532
6. B.D. Trapp, J. Peterson, R.M. Ransohoff, and R. Rudick Axonal transectionin the lesion of multiple sclerosis N Engl J Med 338 1998 278 285
7. B.D. Trapp, R. Ransohoff, and R. Rudick Axonal pathology in multiple sclerosis: relationship to neurologic disability Curr Opin Neurol 12 1999 295 302 Review
8. B. Ferguson, M.K. Matyszak, and M.M. Esiri Axonal damage in acute multiple sclerosis lesions Brain 120 1997 393 399
9. N. Evangelou, D. Konz, and M.M. Esiri Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis Brain 123 2000 1845 1849
10. T. Kuhlmann, G. Lingfeld, and A. Bitsch Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time Brain 125 Pt 10 2002 2202 2212
11. M. Filippi, D.W. Paty, and L. Kappos Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study Neurology 45 2 1995 255 260 Feb
12. M. Filippi Non-conventional MR techniques in monitoring MS activity and evolution Electroencephalogr Clin Neurophysiol Suppl 50 1999 565 569 Review
13. M. Filippi, M. Bozzali, and M. Rovaris Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis Brain 126 2003 433 437
14. D. Katz, J.K. Taubenberger, and B. Cannella Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis Ann Neurol 34 1993 661 669
15. C. Confavreux, S. Vukusic, and P. Adeleine Early clinical predictors and progression of irreversible disability: an amnestic process Brain 126 Pt 4 2003 770 782
16. M. Kremenchutzky, G.P.A. Rice, and J. Baskerville The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of disease Brain 129 2006 584 594
17. C. Confavreux, and S. Vukusic Natural history of multiple sclerosis: a unifying concept Brain 129 2006 a 606 616
18. C. Confavreux, and S. Vukusic Age at disability milestones in multiple sclerosis Brain 129 2006 b 595 605
19. H. Tremlett, M. Yousefi, and V. Devonshire Impact of multiple sclerosis on progression diminished with time Neurology 73 2009 1616 1623
20. E. Leray, J. Yaouanq, and E. Le Page Brain 133 2010 1900 1913
21. A. Scalfari, A. Neuhaus, and A. Degenhardt Brain 133 2010 1914 1929
22. J.R. Wujek, C. Bjartmar, and E. Richer Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis J Neuropathol Exp Neurol 61 1 2002 23 32
23. G. Lovas, N. Szilágyi, and K. Majtényi Axonal changes in chronic demyelinated cervical spinal cord plaques Brain 123 2000 308 317 Feb
24. C. Bjatmar, J.R. Wujek, and B.D. Trapp Axonal loss in the pathology of MS: consequences for understanding the progressive phase of disease J Neurol Sci 15 206 2003 165 171
25. N. Evangelou, G.C. DeLuca, and T. Owens Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions Brain 128 2005 29
26. G.C. DeLuca, G.C. Ebers, and M.M. Esiri Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts Brain 127 2004 1009 1018
27. G.C. DeLuca, K. Williams, and N. Evangelou The contribution of demyelination to axonal loss in multiple sclerosis Brain 129 2006 1507 1516
28. C. Casserly, and G. Ebers Relapses do not matter in relation to long-term disability: yes MSJ 17 12 2011 1412 1414
29. F.D. Lublin Relapses do not matter inrelation to long-term disability: no (they do) MSJ 17 12 2011 1415 1416
30. B.D. Trapp, and K.A. Nave Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 31 2008 247 269
31. H. Lassmann Multiple sclerosis: is there neurodegeneration independent frinflammation? J Neurol Sci 259 2007 3 6
32. I.V. Allen, and S.R. McKeown A histochemical and biochemical study of macroscopically normal white matter in multiple sclerosis J Neurol Sci 41 1979 81-81
33. C. Bjartmar, R.P. Kinkel, and G. Kidd Axonal loss in normal-appearing white matter in a patient with acute MS Neurology 57 2001 1248 1252
34. N. Evangelou, M.M. Esiri, and S. Smith Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis Ann Neurol 47 2000 391 395
35. A. Kutzelnigg, C.F. Lucchinetti, and C. Stadelmann Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2005 2705 2712
36. A. Seewann, H. Vrenken, and P. van der Valk Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis Arch Neurol 66 2009 601 609
37. R.A. Sobel, and G.W. Moore 8th ed. S. Love, DN. Louis, DW. Ellison, Demyelinating diseases in Greenfield's neuropathology 2 2008 University Press Oxford 1608 5013
38. B. Brownell, and J.T. Hughes The distribution of plaques in the cerebrum in multiple sclerosis J Neurol Neurosurg Psychiatry 25 1962 315 320
39. D. Kid, B. Barkhof, and R. McConnell Cortical lesions in multiple sclerosis Brain 122 1999 7 26
40. J.W. Peterson, L. Bo, and S. Mork Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions Ann Neurol 50 2001 389 400
41. J.J. Geurts, and F. Barkhof Grey matter pathology in multiple sclerosis Lancet Neurol 7 9 2008 841 851
42. I. Bo, C.A. Vedeler, and H.L. Nyland Subpial demyelination in cerebral cortex of multiple sclerosis patients J Neuropath Exp Neurol 62 2003 723 732
43. M. Vercellino, F. Plano, and VottaB. et Gray matter pathology in multiple sclerosis J Neuropath Exp Neurol 64 2005 1101 1107
44. J. Spat, ChaixR, and B. Mamoli Epileptic and non-epileptic seizures in multiple sclerosis J Neurol 248 2001 2 9
45. M.P. Amato, BartolozziMI, and V. Zipoli Neocortical volume decrease in relapsing remitting MS patients with mild cognitive impairment Neurology 63 2004 89 93
46. A. Kutzelnigg, J.C. Faber-Rod, and J. Bauer Widespread demyelination in cerebellar cortex in multiple sclerosis Brain Pathol 17 2007 38 44
47. C.P. Gilmore, I. Donaldson, and L. Bo Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter and spinal cord J Neurol Neurosurg Psychiatry 80 2 2009 182 187
48. C.P. Gilmore, G.C. DeLuca, and L. Bö Spinal cord neuronal pathology in multiple sclerosis Brain Pathol 19 4 2009 642 649
49. L. Bö, J.J. Geurts, and P. van der Valk Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis Arch Neurol J 64 1 2007 76 80
50. L. Bø, C.A. Vedeler, and H. Nyland Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration Mult Scler 9 4 2003 323 331
51. B.P. Brink, R. Veerhuis, and E.C. Breij The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions J Neuropath Exp Neurol 64 2005 147 155
52. J. Van Horsen, B.P. Brink, and H.E. de Vries The blood brain barrier in multiple sclerosis lesions J Neuropathol Exp Neurol 66 2007 321 328
53. H. Lassmann A dynamic view of the blood brain barrier in active multiple sclerosis lesions Ann Neurol 70 2011 1 2
54. R. Magliozzi, O. Howell, and A. Vora Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology Brain 130 2007 1089 1104
55. O.W. Howell, C.A. Reeves, R. Nicholas, and D. Carassiti Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis Brain 134 Pt 9 2011 2755 2771
56. E.J. Kooi, J.J. Geurts, and J. van Horssen Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis J Neuropathol Exp Neurol 68 9 2009 1021 1028
57. C. Lucchinetti, and F. Popescu Inflammatory cortical demyelination in early multiple sclerosis N Engl J Med 365 23 2011 2188 2197
58. B. Popescu, R. Bunyan, and J. Parisi A case of multiple sclerosis presenting with inflammatory cortical demyelination Neurology 76 2011 1705 1710
59. B. Popescu, and C. Lucchinetti Menigeal and cortical grey matter pathology in multiple sclerosis BMC Neurol 12 2012 1 8
60. F. Cotton, H.L. Weiner, and F.A. Jolesz MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals Neurology 2003 606064 606146
61. A. Seewann, H. Vrenken, and D.L. Kooi Imaging the tip of the iceberg;visualisation of cortical lesions in multiple sclerosis Mult Scler 2011
62. J.J. Geurts, L. Bo, and P. Powels Cortical lesions in multiple sclerosis presenting combined postmorten MR imaging and histopathology AJNR - Am J Neurorad 26 2007 572 577
63. M. Cercignani, M. Bozzali, and G. Iannucci Magnetisation transfer ratio and mean diffusity of normal appearing white and grey matter from patients with multiple sclerosis J Neurol Neurosurg Psichiatry 70 2001 311 317
64. H. Vrenken, J.J. Geurts, and D.I. Knol Whole brain T1 mapping in multiple sclerosis:global changes of normal-appearing gray and white matter Radiology 240 2006 811 820
65. J.J. Geurts, I.E. Reuling, and H. Vrenken MR spectroscopic evidence for thalamic and hippocampal but not cortical damage in multiple sclerosis Magn Reson Med 55 2006 478 483
66. B. Simon, S. Schmidt, and C. Lukas Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla Eur Radiol 20 2010 1675 1680
67. S. Birgit, S. Stephan, and L. Carsten Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Telsa Eur Radiol 20 7 2010 1675 1680 July
68. M. Calabrese, M. Fillipi, and P. Gallo Cortical lesions in multiple sclerosis Nat Rev Neurol 6 2010 438 444
69. M. Calabrese, M. Fillipi, and M. Rovaris Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study Mult Scler 15 2009 36 41
70. E. Fisher, J.C. Lee, and K. Nakamura Gray matter atrophy in multiple sclerosis: a longitudinal study Ann Neurol 64 2008 255 265
71. C.C. Mainero, T. Benner, and A. Radding In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI Neurology 73 2009 941 948
72. M. Filippi, M.A. Rocca, and M.A. Horsfield Imaging cortical damage and dysfunction in multiple sclerosis JAMA Neurol 70 5 2013 May 556 564
73. I.D. Kilsdonk, W.L. de Graaf, and A.L. Soriano Multicontrast MR imaging at 7 T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR AJNR Am J Neuroradiol 34 4 2013 791 796
74. S. Hannoun, F. Durand-Dubief, and C. Confavreux Diffusion tensor-MRI evidence for extra-axonal neuronal degeneration in caudate and thalamic nuclei of patients with multiple sclerosis AJNR Am J Neuroradiol 33 7 2012 1363 1368
75. H.E. Hulst, and J. Geurts Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol 11 2011 153
76. A. Cifelli, ArridgeM, and P. Jezzard Thalamic neurodegeneration in multiple sclerosis Ann Neurol 53 2002 650 653
77. R. Zivadinov, N. Bergsland, and O. Dolezal Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years AJNR - Am J Neuroradiol 2013
78. C. Wegner, M.M. Esiri, and S.A. Chance Neocortical, neuronal, synaptic and glial loss in multiple sclerosis Neurology 67 2006 960 967
79. D.H. Miller, F. Barhof, and J.A. Frank Measurement of atrophy in multiple sclerosis; pathological basis, methodological aspets and clinical relevance Brain 125 2002 1676 1695
80. J.J. Geurts, M. Calabrese, and E. Fisher Measurement and clinical effect of grey matter pathology in multiple sclerosis Lancet Neurol 2012
81. C.M. Dalton, D.T. Chardt, and G.R. Davies Early development of multiple asclerosis is associated with progressive gray matter atrophy in patients presenting with clinically isolated syndrome Brain 127 2004 1101 1110
82. E. Raz, M. Cercignani, and E. Sbardella Gray and white matter changes after 1 year after first clinical episode of multiple sclerosis Radiology 2010 257448 257453
83. J.J. Geurts The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately: yes Mult Scler May 18 5 2012 559 560
84. R.A. Rudick, and E. Fisher Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): yes Mult Scler 19 8 2013 1003 1004 Jul
85. M. Filippi, and M. Rocca Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year of treatment): no Mult Scler 19 8 2013 1005 1006 Jul